Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.

You may also be interested in...

No Zafgen IPO Yet; It Plans a $40M Crossover Round

The private obesity company will do a mezzanine venture financing that brings in at least one public-oriented investor before it heads, presumably, toward an IPO. That round is slated to close in a month or so. Around the same time, Zafgen will present final Phase II data for its beloranib.

Financings Of The Fortnight Sees A Venture Capital Trend: Identify And Bring In The Buyer Early

Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.

Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes

The sole investor in a $34 million Series A financing, Third Rock hopes Ember can be a pioneer in development of obesity drugs that augment brown fat levels.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts